Faculty introduction, disclosures

Introductory content: review of NASH Epidemiology: Statistics Disease burden, associated metabolic comorbidities, and complications: Cirrhosis, hepatocellular carcinoma, and end-stage liver disease Pathophysiology: Incretins (GLP-1), insulin resistance (and role of lipophilic bile acids) Evidence-based identification, diagnosis, and risk stratification Including patients with metabolic syndrome and type 2 diabetes Impact of early recognition

Treatment of NASH Pharmacologic: o   Patients without diabetes o   Patients with diabetes: roles of pioglitazone, available GLP-1 receptor agonists, metformin Emerging pharmacotherapies with activity at the: Farnesoid X-activated receptor GLP-1 receptor / glucagon receptor Acetyl-CoA carboxylase Guideline-based disease and treatment monitoring Efficacy Liver fibrosis progression Hepatocellular inflammation Metabolic effects Safety and tolerability Special populations, including cirrhosis Non-pharmacologic treatment and management of comorbidities Multidisciplinary care, specialist referral Patient case(s)

Conclusions and best practice recap

By the end of the session the participant will be able to:

• Summarize the healthcare burden unique to patients with NASH and challenges to optimal identification and management.
• Explain best practices in the identification of patients with NASH and those patients with the highest risk of suboptimal outcomes.
• Recall the impact of present and emerging pharmacotherapies for NASH on liver fibrosis and hepatocellular inflammation.
• Formulate a treatment plan for a patient with NASH.

ACCME Activity #202296380

ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.

Faculty Disclosure: Sammy Saab, MD, MPH, AGAF, FAASLD, FACG, Professor of Medicine and Surgery, David Geffen School of Medicine at UCLA, has received financial compensation for consulting and/or speakers bureau work from Abbvie, Gilead, Salix, Eisai, Exelixis, and Mallinckrodt.

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.

Faculty will discuss off-label uses.

All relevant financial relationships have been mitigated.

ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Commercial Support Disclosure: This program is supported by an educational grant from Merck.

• Read the learning objectives above
• Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
• View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
• Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
• Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

*Required to view Printable PDF Version